Idorsia’s Quviviq Needs To Rise And Shine After Slow Launch
US Coverage Negotiations And Celebrity DTC Will Be Significant
The company’s Quviviq launch has fallen short of early expectations, but Idorsia believes a patient approach will pay off for the blockbuster-tipped insomnia treatment.
You may also be interested in...
The prospects of lucerastat becoming Idorsia's second drug to be filed with regulators, after the insomnia treatment daridorexant, look slim after a Phase III fail for the Fabry disease therapy.
GSK’s PD-1 inhibitor will not be able to make up much ground on Keytruda, but new studies suggest it is a match for the market-leading PD-1 inhibitors.
AC Immune has seen two big disappointments in its Alzheimer’s pipeline this year, but its partner Johnson & Johnson has put its faith in a novel vaccine-like approach to targeting the disease.